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Objective: The identification of biological markers in order to assess different aspects of COPD 
is an area of growing interest. The objective of this study was to investigate whether levels of 
procalcitonin (PCT), C-reactive protein (CRP), and neopterin in COPD patients could be useful 
in identifying the etiological origin of the exacerbation and assessing its prognosis.
Methods: We included 318 consecutive COPD patients: 46 in a stable phase, 217 undergoing 
an exacerbation, and 55 with pneumonia. A serum sample was collected from each patient 
at the time of being included in the study. A second sample was also collected 1 month later 
from 23 patients in the exacerbation group. We compared the characteristics, biomarker levels, 
microbiological findings, and prognosis in each patient group. PCT and CRP were measured 
using an immunofluorescence assay. Neopterin levels were measured using a competitive 
immunoassay.
Results: PCT and CRP showed significant differences among the three patient groups, being 
higher in patients with pneumonia, followed by patients with exacerbation (P , 0.0001). 
For the 23 patients with paired samples, PCT and CRP levels decreased 1 month after the 
exacerbation episode, while neopterin increased. Neopterin showed significantly lower levels in 
exacerbations with isolation of pathogenic bacteria, but no differences were found for PCT and 
CRP. No significant differences were found when comparing biomarker levels according to the 
Gram result: PCT (P = 0.191), CRP (P = 0.080), and neopterin (P = 0.109). However, median 
values of PCT and CRP were high for Streptococcus pneumoniae, Staphylococcus aureus, and 
enterobacteria. All biomarkers were higher in patients who died within 1 month after the sample 
collection than in patients who died later on.
Conclusions: According to our results, biomarker levels vary depending on the clinical status. 
However, the identification of the etiology of infectious exacerbation by means of circulating 
biomarkers is encouraging, but its main disadvantage is the absence of a microbiological gold 
standard, to definitively demonstrate their value. High biomarker levels during an exacerbation 
episode correlate with the short-term prognosis, and therefore their measurement can be useful 
for COPD management.
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Introduction
Acute exacerbations of COPD can be precipitated by bacterial and viral infections, and 
by common pollutants such as tobacco and air pollution. But in up to 30% of cases, 
the etiological diagnosis of an exacerbation cannot be achieved.1 On the other hand, 
several factors have been suggested to predict the overall prognosis of COPD, such 
as the decline in FEV1, the BODE index, the frequency and severity of exacerbations, 
and the influence of systemic inflammation.2–5International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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An area of growing interest is to identify biological markers 
that could assess different aspects of COPD. Pulmonary 
biomarkers have been measured mainly in bronchoalveolar 
lavage, induced sputum, and exhaled breath condensate with 
promising results, but the sampling procedure is invasive 
and for some assays the variability is very high.6 A recent 
approach is also the measurement of systemic biomarkers 
that may provide additional information.7 Several studies have 
attempted to examine different inflammatory markers during 
stable state and during exacerbations,8,9 in order to correlate 
their levels with different factors, such as the inflammatory 
basal status, the etiological origin of the exacerbation, as well 
as its prognosis, and the risk of mortality.7 In this regard, we 
have evaluated 3 biomarkers: procalcitonin (PCT), C-reactive 
protein (CRP), and neopterin.
PCT is a specific marker of systemic bacterial infection 
and its levels correlate with the etiology and   severity 
of pneumonia.10,11 Several interventional trials on lower 
respiratory tract infections, including acute COPD 
exacerbations, have also suggested that measuring PCT 
might help to reduce antibiotic prescriptions by means of 
identifying bacterial infections without affecting patient 
recovery.12 CRP is a sensitive acute phase reactant, levels 
of which increase in the presence of infection and during 
chronic inflammatory conditions.13 It has been evaluated 
in different settings of COPD patients, in order to establish 
possible association with basal systemic inflammation in the 
stable period, presence of cardiovascular risk events, disease 
prognosis and identification of infectious exacerbations.14,15 
Neopterin acts as a mediator of cell immunity against intra-
cellular pathogens16 and in lower respiratory tract infections 
it has shown to improve the discrimination between bacte-
rial and viral origin.17 In patients with community acquired 
pneumonia, neopterin levels have also been shown to 
correlate with the severity of the infection.10 Therefore, 
these three biomarkers have been shown to be associated 
with the etiology of lower respiratory tract infections and 
may be of interest in the identification of exacerbation 
episodes that could benefit from antibiotic treatment. These 
biomarkers have also been reported as markers of severity 
and prognosis.
The objectives of this study are 3-fold: first to determine 
the levels of inflammatory markers in COPD patients in a 
clinically stable period, during an exacerbation and during 
pneumonia; second, to establish if the biomarker levels, 
together with the presence of clinical symptoms, can help to 
identify the etiological origin of the exacerbations; finally, to 
examine whether biomarkers can be used to predict short- and 
long-term prognosis after an exacerbation episode.
Patients and methods
setting and study population
We included 318 consecutive adult COPD patients from 
September 2001 to September 2005, who were admitted 
to the Hospital Universitari Germans Trias i Pujol and the 
Hospital de Sant Boi de Llobregat (Spain). Ethical approval 
was given by the Ethics Committee from both institutions 
and written informed consents were obtained.
The diagnosis of COPD was based on clinical history, 
physical examination and spirometric criteria according 
to the Spanish Society of Pneumology and Thoracic 
Surgery (SEPAR) guidelines.18 The severity of the disease 
was categorized into mild (80% , FEV1, 60%), moder-
ate (59% , FEV1 , 40%) and severe (FEV1 , 40%).18 
Exclusion criteria were as follows: patients with history 
of asthma, cystic fibrosis or active pulmonary tuberculosis, 
and patients with no adequate clinical samples available 
(serum samples).
The study population consisted of 46 COPD patients during 
a clinically stable phase (without exacerbation or pneumonia 
within at least 1 or 2 months, respectively); 217 undergoing 
an exacerbation; and 55 COPD patients diagnosed with 
pneumonia. Stable patients were recruited during scheduled 
visits, in order to define a baseline inflammatory response and 
for comparison with the exacerbation group. Exacerbation 
was defined as an acute worsening of the patient’s condition 
from stable state and beyond normal day-to-day variations, 
which presents with worsened dyspnea; worsened sputum 
volume and/or change in its color; or any combination of these 
symptoms, and requires a change in regular medication.19 
Pneumonia was defined by clinical (presence of fever, cough, 
dyspnea) and radiographic signs (pneumonic infiltrate in the 
chest radiograph), as well as clinical evolution, assessed by 
expert clinicians and radiologists.20
We collected sputum samples and blood cultures for 
microscopic examination and standard bacteriological cul-
ture, and urine for antigen detection from those patients in the 
pneumonia and exacerbation groups, in order to identify the 
etiological origin.21 A total of 272 sputum samples (217 from 
exacerbated patients and 55 from patients with pneumonia) 
was collected (1 sample per patient). Sputum samples were 
transported immediately to the microbiology laboratory or 
refrigerated until transport. After microscopic examination, 
only those samples with ,25 squamous epithelial cells International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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and .25 polymorphonuclears per low-power field were 
cultured.22
Pneumococcal pneumonia was diagnosed by isolation of 
Streptococcus pneumoniae from blood culture or by detection 
of pneumococcal capsular polysaccharide antigen in urine 
samples by counterimmunoelectrophoresis.23–25 Legionella 
pneumonia was diagnosed by urinary antigen detection of 
Legionella pneumophila serogroup 1 by enzyme immuno-
assay (Bartels EIA Legionella urinary antigen. Bartels Inc., 
Trinity Biotech Company, Wicklow, Ireland).
Epidemiological (age, gender) and clinical history data 
(presence of comorbidities, smoking status, COPD status, 
FEV1, chronic oxygen therapy, previous steroid and antibiotic 
therapy) were collected. We also collected information from the 
exacerbated patients on the characteristics of the exacerbation 
episodes (Anthonisen criteria, individual clinical symptoms, 
microbiological findings, length of hospitalization).
Patient follow-up
A blood sample was collected from each patient at the time 
of inclusion into the study: hospital admission (for the exac-
erbation and pneumonia group) or during the scheduled visit 
(for the stable group). Two years later, clinical files were ret-
rospectively reviewed and the patient follow-up was recorded 
in order to assess clinical outcome (readmission, days until 
next episode, number of exacerbations within 1 year, and 
days until death, when that occurred).
Among the 217 exacerbated patients, from 23 we also 
collected a second serum sample 1 month later, when the 
patient was in the recovery phase. All serum samples were 
stored at –20°C until biomarkers were measured.
Biomarker measurement
PCT and CRP were measured with an immunofluorescent 
assay (Kryptor Brahms AG, Hennigsdorf, Germany) with 
functional sensitivities of 0.06 ng/mL and 0.15 µg/mL, 
respectively. The intra- and inter-assay coefficients for PCT 
at a sample concentration of 0.2 ng/mL were 10%. The intra- 
and inter-assay coefficients for CRP at a sample concentration 
of 1.03 µg/mL were 5.1% and 14.2%, respectively. Neopterin 
levels were measured with a competitive immunoassay fol-
lowing the manufacturers’ instructions (Neopterin ELISA, 
IBL, Hamburg, Germany). The assay lower limit of detec-
tion was 0.7 nmol/L. The intra-assay coefficient at a sample 
concentration of 7.7 to 48 nmol/L was 3.6% to 6.8%, and 
inter-assay coefficient at a sample range of 7.4 to 59 nmol/L 
was 7.6% to 10.3%.
statistical analysis
Discrete variables are expressed as counts (percentages) 
and continuous variables as mean ± standard deviation (SD) 
or median (interquartile range [IQR]). The comparison of 
groups was performed using the Mann–Whitney U test, 
Kruskal–Wallis test or Wilcoxon matched-pair test, as 
appropriate. Mann–Whitney was applied when assessing 
if biomarker levels varied significantly when considering 
the presence of several variables (comorbidities, steroid/
antibiotic/oxygen treatment, smoking status) at baseline 
and at exacerbation (Table 2). This test was also applied for 
comparing biomarker levels according to the characteristics 
of the exacerbation episode (Anthonisen criteria, presence 
of individual symptoms and sputum culture result), the need 
for readmission, and patient survival. Kruskal–Wallis was 
applied when assessing if there were differences in biomarker 
levels between the 3 patient groups (stable vs exacerbated 
vs pneumonia). The Wilcoxon matched-paired test was 
applied when comparing biomarker levels for the subgroup 
of 23 patients with second samples. Pearson’s chi-square 
test was applied when comparing baseline characteristics 
between the 3 patient groups and between the exacerbated 
patients according to the sputum culture result. Correlation 
analyses were performed using Spearman’s correlation. 
The use of biomarkers and symptoms in identifying prob-
able bacterial origin was investigated by receiver operating 
characteristic (ROC) analysis. Sample size was calculated 
in order to find differences in the biomarker levels between 
exacerbated patients with probable bacterial origin and 
those of noninfectious origin. In order to detect statistically 
significant differences between these 2 groups and supposing 
a standardized size effect of 0.60, a significance level of 5% 
(unilateral), and a beta risk of 20%, 97 patients are needed 
in both groups. To assess the influence of PCT, CRP, and 
neopterin levels, age and COPD severity on 2-year survival, 
Cox-regression univariate and multivariate analyses were 
performed. The time to death up to 2 year was analyzed by 
Kaplan–Meier survival curves, and compared by the log-rank 
test. Associations were considered statistically significant 
if P value was ,0.05. The commercial statistical software 
packages used were SPSS 15.0 (SPSS Inc, Chicago, IL) and 
GraphPad Prism 5 (Graph Pad Inc, San Diego, CA).
Results
study population
The characteristics of the 318 patients included in the 
study, according to their corresponding group are shown in International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Table 1. FEV1 measurement at the time of study inclusion 
was recorded for 248 patients (78%). For the remaining 
70 patients, FEV1 was not available, but all of them were 
clinically and spirometrically diagnosed with COPD. 
Overall, it was a predominantly male COPD population 
with a mean age of 71.21 years (SD: 10.10). Comparison of 
baseline characteristics according to patient group showed 
statistical differences for, smoking status, presence of con-
gestive heart failure, severity of COPD, and use of chronic 
oxygen therapy and steroid treatment (Table 1). Some of 
the differences found can be explained by the fact that 
exacerbated patients have a more severe COPD, with higher 
frequencies of chronic oxygen therapy and steroid treatment. 
Interestingly exacerbated patients also had a higher frequency 
of congestive heart failure. When considering only exacer-
bated patients, and comparing population characteristics 
according to sputum culture results (normal flora/negative 
or pathogenic bacteria), we found statistical differences only 
for the presence of renal disease (Table 1).
We also assessed whether PCT, CRP, and neopterin 
levels could be affected by the presence of comorbidities, 
smoking status, chronic oxygen therapy, and previous 
steroid and antibiotic treatment in the following 2 groups: 
patients at stable state (baseline) and patients undergoing an 
exacerbation (Table 2). Spearman’s correlations were 0.087 
(P = 0.219) for PCT, –0.035 (P = 0.621) for CRP, and 0.055 
Table 1 study population characteristics according to patient group: calculation of p values for the comparison of clinical and 
demographical characteristics for the 3 patient groups and for exacerbated patients according to the sputum culture result
Characteristic Study population Exacerbated patients
Stable  
n = 46 (%)
Exacerbated  
n = 217 (%)
Pneumonia  
n = 55 (%)
p value Normal flora/neg  
n = 85 (%)
Pathogenic bacteria  
n = 76 (%)
p value
Age
Mean ± sD 70.9 ± 10.3 71.4 ± 9.9 69.3 ± 10.5 0.329 72.6 ± 8.8 72.3 ± 8.7 0.88
Gender
Female 1 (2.2) 13 (6) 1 (1.8) 0.290 4 (4.7) 4 (5.3) 0.260
Male 45 (97.8) 204 (94) 54 (98.2) 81 (95.3) 72 (94.7)
Current smoker
Yes 15 (32.6) 38 (17.5) 14 (25.5) 0.004* 13 (15.3) 8 (10.5) 0.633
ex-smoker 23 (50) 150 (69.1) 38 (69.1) 60 (70.6) 9 (11.8)
nonsmoker – 23 (10.6) 1 (1.8) 9 (10.6) 58 (76.4)
not available 8 (17.4) 6 (2.8) 2 (3.6) 3 (3.5) 1 (1.3)
Comorbidities
neoplasia 8 (17.4) 29 (13.4) 9 (16.4) 0.525 12 (14.5) 9 (11.8) 0.627
Liver disease – 10 (4.6) 5 (9.1) 0.107 2 (2.4) 4 (5.3) 0.346
Congestive heart failure 5 (10.9) 61 (28.1) 9 (16.4) 0.047* 24 (28.9) 25 (32.9) 0.587
Arterial hypertension 14 (30.4) 82 (37.8) 17 (30.9) 0.634 39 (47) 27 (35.5) 0.143
Cerebrovascular disease 2 (4.3) 18 (8.3) 3 (5.5) 0.725 10 (12) 5 (6.6) 0.239
renal disease 4 (8.7) 14 (6.5) 5 (9.1) 0.513 9 (10.8) 1 (1.3) 0.013*
Diabetes 12 (26.1) 52 (24) 8 (14.5) 0.132 24 (28.9) 18 (23.7) 0.45
not available 8 (7.4) 3 (1.4) – – –
Severity COPD (FEV1)
,40% 11 (24) 102 (47) 25 (45.5) 0.005* 44 (51.8) 38 (50) 0.241
40%–59% 22 (47.8) 51 (23.5) 13 (23.6) 19 (22.3) 16 (21)
60%–80% 3 (6.5) 17 (7.8) 4 (7.3) 5 (5.9) 8 (10.6)
not available 10 (21.7) 47 (21.7) 13 (23.6) 17 (20) 14 (18.4)
Chronic oxygen  
therapy
Yes 2 (4.3) 61 (28.1) 13 (23.6) 0.009* 29 (34.1) 22 (29) 0.420
not available – 5 (2.3) 1 (1.8) 1 (1.2) 1 (1.3)
Steroid treatment
Yes 7 (15.2) 121 (55.8) 28 (50.9) 0.001* 50 (58.8) 48 (63.1) 0.592
Inhaled/oral
Inhaled – 103 (85.1) 25 (45.5) 0.001* 39 (78) 43 (89.6) 0.295
Oral 4 (8.7) 10 (8.3) 2 (3.6) 6 (12) 3 (6.3)
Not specified 3 (6.5) 8 (6.6) 1 (1.8) 5 (10) 2 (4.2)
Note: *p was considered significant if the value was ,0.05.
Abbreviation: sD, standard deviation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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(P = 0.434) for neopterin, when considering COPD severity 
classified according to FEV1.
Biomarkers and clinical state
Circulating biomarker levels in the stable population, at 
exacerbation, and during pneumonia are shown in Figure 1. 
PCT and CRP levels showed significant differences among 
the 3 groups of patients, being lower during clinical stability 
and higher during pneumonia (P , 0.0001). In contrast, neop-
terin levels did not show any significant difference. When 
considering the subgroup of patients with paired samples, 
PCT (P = 0.0788) and CRP (P = 0.0181) levels decreased 
at 1 month after the exacerbation episode (recovery phase), 
while neopterin levels increased significantly (P = 0.0325) 
(Figure 2).
Biomarkers and exacerbation episodes
etiology of the exacerbation
The characteristics of the 217 exacerbation episodes are shown 
in Table 3. According to the classification of Anthonisen,26 
none of the biomarker levels differed significantly: PCT 
(P = 0.085), CRP (P = 0.495), and neopterin (P = 0.383). 
When considering the presence of individual symptoms, 
such as fever and impairment of respiratory failure (defined 
as ratio of the partial pressure of oxygen in arterial blood 
to the inspired oxygen fraction [PaO2/FiO2] ,250 with 
respiratory rate .30/min), no biomarker showed significant 
difference: PCT (P = 0.370 and P = 0.827), CRP (P = 0.350 
and P = 0.708), and neopterin (P = 0.325 and P = 0.837). 
When mucopurulent expectoration was present, neopterin 
levels were significantly lower (P = 0.039) while CRP levels 
were higher with almost statistical significance (P = 0.058), 
and no significance was found for PCT (P = 0.533).
Among the sputum samples collected from the exac-
erbated patients, 163 were valuable for microbiological 
culture according to Murray’s criteria.22 In 85 cases the result 
was normal flora or a negative culture result; in 76 cases 
potential pathogenic bacteria were isolated, and for the 
remaining 2 cases, information was missing. Normal flora 
was defined as microorganisms belonging to oropharyngeal 
or gastrointestinal flora not usually involved in respiratory 
infections in nonimmunocompromised patients.22
Interestingly, neopterin (P = 0.018) levels were signifi-
cantly higher when the culture result was normal flora or 
negative (18.85 ng/mL; IQR 10.48–36.79) in comparison to 
isolation of predominant bacteria (14.9 ng/mL; IQR 8.58–
20.9). In contrast, PCT (P = 0.620) and CRP (P = 0.568) levels 
did not show any significant differences. For exacerbations 
with normal flora or negative culture results, PCT and CRP 
levels were 0.10 ng/mL (IQR 0.06–0.21) and 88.66 µg/mL 
Table 2 Values of p for each biomarker when considering the presence of confounding variables at baseline and at exacerbation
PCT Neopterin CRP
Baseline Exacerbation Baseline Exacerbation Baseline Exacerbation
Presence of comorbidities
Arterial hypertension 0.315 0.032* 0.830 0.006* 0.987 0.636
Diabetes 0.918 0.047* 0.986 0.063 0.345 0.662
neoplastic disease 0.351 0.835 0.171 0.704 0.568 0.613
Liver disease – 0.256 – 0.890 – 0.299
Congestive heart failure 0.325 0.917 0.909 0.389 0.225 0.149
Cerebrovascular disease 0.945 0.216 0.032* 0.741 1 0.720
renal disease 0.886 0.101 0.510 0.001* 0.886 0.820
Steroid therapy
Yes vs no 0.533 0.049* 0.901 0.031* 0.135 0.086
Oral vs inhaled – 0.347 – 0.322 – 0.099
Smoking status
Current smokers vs never smokers – 0.659 – 0.861 – 0.935
Current smokers vs ex-smokers 0.311 0.253 0.322 0.964 0.897 0.497
never smokers vs ex-smokers – 0.096 – 0.694 – 0.581
Previous antibiotic therapy
Yes vs no 1 0.664 0.615 0.554 0.308 0.274
Home oxygen
Yes vs no 0.307 0.060 0.291 0.104 0.174 0.674
Severity COPD
Mild-moderate-severe 0.548 0.146 0.799 0.179 0.900 0.688
Note: *p was considered significant if the value was ,0.05.
Abbreviations: CrP, C-reactive protein; PCT, procalcitonin.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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(IQR 38.04–164.35),   respectively. For exacerbations with 
pathogenic bacteria isolation, PCT and CRP levels were 
0.10 ng/mL (IQR 0.07–0.22) and 88.61 µg/mL (IQR 
34.89–201.12), respectively.
Regarding only those sputum culture results with patho-
genic bacteria isolated, Gram-negative bacteria accounted 
for 73.7% of all microorganisms recovered; with Haemo-
philus influenzae, Pseudomonas aeruginosa, and Moraxella 
catarrhalis being most frequently isolated (48.2%, 25%, 
and 16% respectively). Gram-positive bacteria accounted 
for 22.3%, with S. pneumoniae being the most frequent 
(88.2%). Aspergillus fumigatus was isolated twice (2.6%), 
and in the last case there was co-infection of S. pneumoniae 
and H. influenzae (1.3%). Levels of PCT, CRP, and neopterin 
according to the microorganism isolated are shown in Table 4. 
No significant differences were found when comparing bio-
marker levels according to the Gram result: PCT (P = 0.191), 
CRP (P = 0.080) and neopterin (P = 0.109). However, the 
median values of PCT and CRP were high for S. pneumoniae, 
Staphylococcus aureus, and enterobacteria.
In order to assess if it was possible to clinically identify 
the etiological origin of the exacerbations, we examined a 
combination of biomarker levels together with the following 
variables: Anthonisen criteria, presence of fever, respiratory 
failure, and mucopurulent expectoration. Areas under the 
ROC curve (AUC) for each biomarker were higher when 
the combination of symptoms and biomarker levels was 
taken into account than when considering biomarker levels 
alone (Figure 3).
exacerbation severity and prognosis
For the 217 patients with an exacerbation, the mean length of 
hospitalization was 12.92 days (SD: 29.20). Spearman’s cor-
relations were 0.171 (P = 0.022) for PCT, 0.150 (P = 0.046) 
for CRP, and 0.148 (P = 0.045) for neopterin. Among these 
patients, 147 (67.7%) had to be readmitted in the following 
year at least once due to a new exacerbation episode and 
no significant differences were found for PCT (P = 0.258), 
CRP (P = 0.778), and neopterin (P = 0.255). The mean 
number of days until the next hospitalization was 210.86 
(median 78). Only neopterin correlated significantly with 
the time until next hospitalization. Thus, the correlations 
were −0.021 (P = 0.803) for PCT, −0.015 (P = 0.863) for 
CRP, and 0.209 (P = 0.012) for neopterin. The number of 
exacerbations within the following year was also recorded 
for each patient. The mean number of exacerbations was 2.27 
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Figure 1 Distribution of procalcitonin (PCT) (ng/mL) (A), C-reactive protein (CrP) (µg/mL) (B), and neopterin (ng/mL) (C) levels according to patient group. PCT levels 
during stable state, exacerbation, and pneumonia are as follows: 0.06 ng/mL (0.04–0.08), 0.10 ng/mL (0.06–0.22), and 0.24 ng/mL (0.1–1.32). CrP levels during stable state, 
exacerbation and pneumonia were as follows: 11.83 µg/mL (5.07–44.90), 88.66 µg/mL (31.69–184.5), and 140.4 µg/mL (67.1–252.5). neopterin levels during stable state, 
exacerbation, and pneumonia are as follows: 17.09 ng/mL (12.53–25.36), 17.43 ng/mL (9.85–27.84), and 22.26 ng/mL (13.31–35.34). Values of PCT and CRP showed significant 
differences among the 3 groups of patients (p , 0.0001), being lower during clinical stability. Neopterin did not show any significant differences.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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(SD: 2.06) and did not correlate with any of the   biomarkers. 
Spearman’s correlations were −0.029 (P = 0.730) for 
PCT, −0.0675 (P = 0.434) for CRP, and −0.115 (P = 0.170) 
for neopterin.
Fifty-five patients died, 41 in the following 2 years, 
and the remaining 14 later on. There were no significant 
differences in biomarker levels between survivors and 
nonsurvivors: PCT (P = 0.061), CRP (P = 0.176), and 
neopterin (P = 0.264), although higher PCT and CRP levels 
were seen in those patients who died than in the survivors. 
The time elapsed between the time the sample was collected 
and the time the patient died was also recorded. There was 
no significant correlation between the time of the death and 
the biomarker levels. Spearman’s correlations were −0.150 
(P = 0.290) for PCT, 0.048 (P = 0.738) for CRP, and −0.222 
(P = 0.111) for neopterin. Nevertheless, the values of all 
biomarkers were higher in the group of patients who died 
within 1 month, decreasing whenever the time of death 
occurred later on (Figure 4). Indeed, PCT (P = 0.046) and 
neopterin (P = 0.044) levels were significantly higher in the 
group of patients who died within 1 month than in patients 
dying later on.
Kaplan–Meier survival curves showing patients accord-
ing to PCT, CRP, and neopterin quartiles are shown in 
Figure 5. In the multivariate Cox regression model analysis, 
age and neopterin levels were the only predictive factors 
independently associated with 2-year survival (P = 0.01 and 
P = 0.048, respectively).
Discussion
Influence of comorbidities  
and previous treatment
In recent years, COPD has been described as an inflam-
matory disease with systemic consequences.4 Circulating 
biomarkers might be influenced by several factors, such as 
the medical treatment or the underlying diseases, which play 
an important role in COPD management. When assessing the 
influence of smoking status, previous treatments, presence 
of comorbidities, and COPD severity itself, it is essential to 
take into account that COPD patients are very heterogeneous. 
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Table 3 Characteristics of the 217 exacerbation episodes
AECOPD characteristics n %
Type of AECOPD according to the Anthonisen 
criteria
I (increased dyspnea, sputum purulence, sputum volume) 114 52.3
II (2 of the above) 25 11.5
III (1 of the above and 1 or more minor findingsa) 67 30.9
Unknown 11 5.1
Symptoms
Fever 100 46.1
respiratory failure 119 54.8
Mucopurulent sputum 150 69.1
Sputum culture result (according to Murray criteria)
Poor quality or culture not done 54 24.9
Normal flora 85 39.2
Pathogenic bacteria 76 35
Unknown 2 0.9
Previous antibiotherapy (before sample collection) 45 20.7
Note: aMinor  findings  include  fever  (.38°C)  without  other  cause;  increased 
wheezing; increased cough; or increased respiratory rate compared with stable 
baseline condition.
Abbreviation: AeCOPD, acute exacerbations of COPD.
Secondly, it is also important to focus on how these factors 
might influence biomarker levels. Our results showed that 
the smoking habit did not statistically influence levels. But 
we found similar PCT, neopterin, and CRP levels in ex-
smokers and current smokers, being higher in both groups 
than in nonsmoker patients. This reinforces the fact that the 
smoking habit causes a low-grade inflammatory response.27 
It has been reported that corticosteroid therapy decreases 
the levels of inflammatory markers, with the exception of 
PCT,28,29 although we found statistically lower values of PCT 
in exacerbated patients treated with corticosteroids. Interest-
ingly, exacerbated patients undergoing corticosteroid therapy 
also had significantly lower levels of neopterin.
COPD can also predispose individuals to the presence of 
other comorbidities, such as arterial hypertension, diabetes, 
and cardiovascular diseases that can potentially influence the 
outcome of COPD itself. So, the coexistence of associated 
diseases is common and can affect COPD disease progression 
and prognosis.30 In our experience, PCT and neopterin levels 
showed significant differences when taking the presence of 
arterial hypertension into account. Higher neopterin levels have 
been found in patients with cardiac and renal diseases.16 To our 
knowledge, PCT levels are not related to chronic disorders.31
Biomarkers and clinical status
Although PCT and CRP levels showed significant differences 
among the three patient groups, there is some overlap between 
the stable and the exacerbation groups. In exacerbated COPD 
patients, PCT levels are higher than in stable patients, although 
the infection might be locally restricted and too unspecific to 
show a notable increase in PCT. This may be due to the fact that 
not all patients might have the same basal levels in the stable 
state, so the increase in individual biomarker levels during an 
exacerbation episode might be different. This is one of the 
reasons that might explain why the ideal approach is probably 
not to establish biomarker cut-off levels for the overall COPD 
population, but to individually monitor patients and assess the 
intra-individual biomarker variation in the long term.
In the COPD stable group, biomarker levels reflect a basal 
local and systemic inflammation. During an exacerbation 
episode, there is an amplification of this basal inflammation, 
and thus there is an increase in inflammatory markers.32 It is 
also important to point out that the severity of the exacerba-
tion episodes could be different for each patient. Parenchymal 
damage in pulmonary tissue may also be present during 
exacerbations, even if not detected by conventional methods, 
such as X-ray. In these cases, biomarker levels may be higher 
than in those without evidence of parenchymal damage. And, 
finally, it is also possible that some patients might underesti-
mate their symptoms, so in these individuals the early detec-
tion of high levels of biomarkers could be beneficial.
When comparing the levels of biomarkers for the 
23 patients with 2 consecutive samples individually, we 
Table 4 number of isolates and levels of PCT, CrP, and neopterin according to the microorganism isolated
Microorganism isolated Number 
isolates (%)
PCT (ng/mL) 
median (IQR)
CRP (μg/mL) 
median (IQR)
Neopterin (ng/mL) 
median (IQR)
Haemophilus influenzae 27 (35.6) 0.09 (0.08–0.14) 69.8 (23.89–160.9) 15.7 (8.34–23.19)
pseudomonas aeruginosa 14 (18.4) 0.11 (0.05–0.23) 78.75 (19.42–181.5) 15.02 (11.39–17.89)
Moraxella catarrhalis 9 (11.8) 0.07 (0.04–0.09) 77.63 (46.8–157.9) 9.87 (6.32–15.64)
enterobacteria 6 (7.9) 0.20 (0.07–0.44) 101.6 (27.83–364.92) 18.02 (12.89–30.17)
Streptococcus pneumoniae 15 (19.8) 0.14 (0.07–0.42) 133.4 (74.77–285.97) 12.42 (6.8–20)
Staphylococcus aureus 2 (2.6) 0.44 307.95 10.83
Aspergillus fumigatus 2 (2.6) 0.15 172.73 16.81
Co-infection S. pneumoniae and H. influenzae 1 (1.3) 0.34 310.7 21.07
Abbreviations: CrP, C-reactive protein; IQr, interquartile range; PCT, procalcitonin.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 receiver operating characteris (rOC) for each biomarker [procalcitonin (PCT) (A), C-reactive protein (CrP) (B), and neopterin (C)] when considering the 
combination of clinical symptoms and biomarker levels with respect to the prediction of exacerbation of probable bacterial origin. The areas under the curve (AUC), standard 
error (SE), and 95% confidence interval (CI) when considering PCT, CRP, and neopterin levels alone were 0.523 (0.168, 0.712–1.38), 0.527 (0.205, 0.721–1.61), and 0.609 
(0.215, 0.389–0.904) respectively. When adding the information provided by all the variables above to the biomarker levels all the AUC increased: 0.663 (0.198, 0.652–1.42) 
for PCT, 0.683 (0.253, 0.6530–1.76) for CrP, and 0.699 (0.267, 0.305–0.867) for neopterin.
found that not all biomarkers had the same behavior over 
time. PCT and CRP decreased in 1 month (recovery phase), 
presumably to individual basal levels. The decrease in PCT 
and CRP has also been reported previously.33 In contrast, 
neopterin levels increased significantly. One possible expla-
nation for this increase is the influence of the corticosteroid 
treatment. Indeed, when analyzing the exacerbated population 
alone, patients who were not on corticosteroid therapy had 
statistically higher levels of neopterin. Of the 23 patients 
with 2 samples, 7 were having corticosteroid therapy and in 
6, levels of neopterin increased in 1 month.
Biomarkers and exacerbation
It is difficult and challenging to identify the exacerbations of 
infectious origin. In fact, between 25% and 50% of COPD 
patients are colonized with potential respiratory pathogens,1 
so the isolation of a predominant microorganism in the 
sputum is not sufficient to determine the etiological origin 
of the exacerbation. In stable COPD patients it is possible 
to isolate potential pathogenic bacteria in sputum samples, 
so the presence of bacteria during an exacerbation does not 
prove its direct involvement in the episode. According to 
the culture result, it is not possible to differentiate between 
infection and colonization. So, a negative result or a normal 
flora result also does not exclude the presence of the micro-
organism responsible of the exacerbation. Therefore, in the 
absence of a gold standard, there is need for new tools to 
identify etiological origin of the episode.
Even if there are no significant differences in PCT and 
CRP among patients with pathogenic bacteria and normal 
flora culture results, it is interesting that AUC values for 
both biomarkers increased when considering variables sug-
gesting infectious origin. Therefore, a relationship between 
biomarkers and infectious etiology is likely.12,34
Although in our study, PCT did not show significant 
differences with the probable etiology of the exacerbation, 
several pieces of evidence reinforce its correlation with bac-
terial origin. Firstly, in an interventionist study conducted 
by Stolz and colleagues,35 PCT guided antibiotic therapy 
in a group of patients undergoing an acute exacerbation, 
significantly reduced the antibiotic prescription without 
negative consequences in the short- and long-term follow-up.   International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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In addition, they found that PCT levels were not associated with 
bacterial sputum isolation, being also in accordance with our 
results. And secondly, PCT levels are significantly increased 
in proven bacterial infections, such as pneumonia, involving 
parenchymal damage and a marked inflammatory response,10 
as occurs in COPD patients and shown in our results.
Interestingly, we found that median CRP and PCT levels 
were high in those exacerbations with isolation of S. pneumo-
niae, S. aureus, and enterobacteria in comparison to patients 
with isolation of other pathogenic microorganisms. In fact, 
S. aureus and S. pneumoniae are able to trigger a significant 
inflammatory response during pulmonary infections.10,36,37
It has been suggested that CRP plays a role during bacterial 
exacerbations, since higher levels of this biomarker have been 
observed in exacerbations with mucopurulent expectoration 
and Anthonisen type I episodes.15,32,33,38 In our study, CRP levels 
were almost significant when mucopurulent sputum was present, 
although no correlation with Anthonisen criteria was found.
Higher neopterin levels were found in the group of 
patients with normal flora or negative culture results, and 
these could reflect episodes of viral etiology.17 Given that 
viruses such as rhinovirus, influenza, and adenovirus play a 
role in stable COPD and in exacerbations episodes,1 it would 
have been interesting to examine their presence in our COPD 
population.
Several factors have been associated with the overall 
prognosis of COPD.2,4 It has been suggested that novel bio-
markers such as copeptin, pro-adrenomedullin, and pro-atrial 
natriuretic peptide in combination with the classical ones, 
such as CRP, are potentially capable of predicting short- and 
long-term outcomes in exacerbations of COPD.33,39,40 In our 
study, the mean number of exacerbations per year was 2.27, 
and none of the biomarker levels correlated significantly. 
Although no biomarker showed a relationship with the 
number of exacerbations in the following year, neopterin cor-
related significantly with the time to the next exacerbation. In 
addition, neopterin and age were the only predictive factors 
independently associated with 2-year survival. Patients who 
died in the first month after the sample was collected had 
significantly higher levels of PCT and neopterin. It is then 
reasonable to hypothesize that the punctual measurement of 
some biomarkers during an exacerbation episode might help International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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in identifying severe patients with a higher risk of death in 
the short term, being useful for the identification of short-
term prognosis.
Limitations
This study has some limitations. First, the low number of 
patients in some of the analysis subgroups is insufficient to 
draw robust conclusions. It is for this reason that further stud-
ies including a larger number of patients will be necessary. 
Second, we did not investigate for the presence of virus either 
by serological studies or molecular methods. And, finally, we 
did not take a second serum sample from all the exacerbated 
patients 1 month later. However, our study provides useful 
data about the usefulness of biomarkers in the field of COPD 
exacerbations.
Conclusion
In summary, this study provides additional data on the use of 
systemic biomarkers in COPD patients. Biomarkers also vary 
depending on the COPD clinical status, when considering 
patients individually. The identification of exacerbation 
etiology by means of circulating biomarkers is encourag-
ing, but has as its main disadvantage the absence of a gold 
standard to definitely demonstrate its value. Nevertheless, 
interventional studies have already demonstrated the potential 
use of biomarkers for this purpose.35 Levels of biomarkers 
were higher in patients who died within 1 month, providing 
information on the short-term prognosis. It may be that the 
combination of serial biomarker measurements with clini-
cal data could help in the understanding and management 
of COPD patients.
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